1.52
0.05 (3.40%)
| Previous Close | 1.47 |
| Open | 1.48 |
| Volume | 839,325 |
| Avg. Volume (3M) | 836,131 |
| Market Cap | 109,366,896 |
| Price / Sales | 3.66 |
| Price / Book | 0.340 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -746.40% |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 14.27% |
| Current Ratio (MRQ) | 6.94 |
| Operating Cash Flow (TTM) | -151.52 M |
| Levered Free Cash Flow (TTM) | -79.27 M |
| Return on Assets (TTM) | -26.62% |
| Return on Equity (TTM) | -59.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Zentalis Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.39% |
| % Held by Institutions | 80.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Matrix Capital Management Company, Lp | 31 Mar 2025 | 13,959,973 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 557.90%) | Buy |
| Median | 7.00 (360.53%) | |
| Low | 4.00 (Wedbush, 163.16%) | Hold |
| Average | 7.00 (360.53%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 1.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 May 2025 | 10.00 (557.89%) | Buy | 1.26 |
| 27 Mar 2025 | 10.00 (557.89%) | Buy | 1.79 | |
| Wedbush | 15 May 2025 | 4.00 (163.16%) | Hold | 1.26 |
| 28 Mar 2025 | 4.00 (163.16%) | Hold | 1.81 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |